On April 23rd, NIA announced OPKO Health (OPK) as its #1 COVID-19 testing play at $2.08 per share and predicted it would go to $3 per share in the following weeks as 98 million shares that were sold short get squeezed. Last week it was announced that New York State was paying OPK's BioReference Labs $150 million for analyzing Covid-19 diagnostic and antibody tests through July 25th. Click here to read an article about it!
OPK reached a high so far today of $2.85 per share for a gain of 37% in 18 trading days!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. This message is meant for informational and educational purposes only and does not provide investment advice.